MedTrace Logo

KVUS at Neoadjuvant CTx of Breast Cancer

NCT03385200 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-12-28

No results posted yet for this study

Summary

Effect of the contrast-enhanced diagnostic ultrasound during neoadjuvant chemotherapy of breast cancer on the achieved tumor size reduction and tolerability of chemotherapy

Conditions

  • Early Primary Breast Cancer

Interventions

DRUG

SonoVue

As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.

Sponsors & Collaborators

  • Univ.-Prof. Dr. med. F. Kiessling

    collaborator UNKNOWN

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Elmar Stickeler, niv.-Prof. Dr. med. · Department of Gynecology and Obstetrics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-12
Primary Completion
2019-06-12
Completion
2019-12-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385200 on ClinicalTrials.gov